Program Director
Raul Santos
The webinar “Severe Dyslipidemias in LATAM: Confronting the Future” has been developed with the aim to comprehensively address the matter of managing patients with severe dyslipidemias, to close knowledge and practice gaps, and reduce clinician uncertainty. Led by Professor Raul Santos, Program Director, the project is a series of thirteen (13) pre- recorded sessions, each 15-20 minutes in length, divided into six (6) presentations given on the first day of the program, focused on Severe Hypertriglyceridemias; seven (7) offered the second day, focused on Severe Hypercholesterolemias. Each session will have the presentation of a panelist highlighting the situation of the Country he/she represents. At the very end of each forum, the session chair will hold 10-minute final wrap up. The videos are also available with Portuguese and Spanish subtitles.
Descrição do programa
O webinar “Dislipidemias graves na America Latina: confrontando o futuro” foi estudado com o objetivo de forma compreensiva a abordar o problema do manejo de pacientes com dislipidemias graves, para fechar as lacunas de conhecimento e prática, reduzir a incerteza do clínico.
Liderado pelo Professor Raul Santos, Diretor do Programa, o projeto baseia-se na criação de uma série de treze (13) sessões pré-gravadas, cada uma com 15-20 minutos de duração, divididas em:
– Seis (6) apresentações realizadas no primeiro dia do programa, com foco em Hipertrigliceridemias Graves;
– Sete (7) ofertados no segundo dia, com foco em Hipercolesterolemias Graves.
Cada sessão contará com a apresentação de um painelista, encarregado de destacar a situação do País que ele/ela representa.
No final de cada fórum, o presidente da sessão fará um encerramento final de 10 minutos e com perguntas e respostas da audiência ao vivo.
Descripción del programa
El webinario “Dislipidemias Severas en LATAM: Confrontando el Futuro” ha sido diseñado con el objetivo de abordar integralmente el manejo de los pacientes con dislipidemias severas, reducir las brechas en el conocimiento y práctica clínica, disminuir la incertidumbre del médico.
El proyecto liderado por el Profesor Raúl Santos, Director del Programa, se basa en la creación de una serie de trece (13) sesiones pregrabadas, cada una de 15-20 minutos de duración, divididas en:
– Seis (6) presentaciones durante el primer día del programa, enfocadas en las Hipertrigliceridemias Severas;
– Siete (7) presentaciones durante la segunda jornada, enfocados en las Hipercolesterolemias Severas.
Cada sesión contará con la presentación de un panelista, encargado de resaltar la situación del País que el/ella representa. Al final de cada foro, el presidente de la sesión realizará un resumen final de 10 minutos y una sesión en vivo de preguntas y respuestas de la audiencia.
Pre-Activity Information
This program, recorded live, is presented by world-renowned medical experts and is designed for endocrine, lipid, and cardiology clinicians practicing in the LATAM Region.
Upon completion of this activity, participants should be able to:
1. Identify appropriate lipid management strategies for patients affected by severe dyslipidemias
2. Describe the efficacy and safety of current and emerging agents for dyslipidemias.
The IAS is proud to present this esteemed global faculty. More information on each faculty member can be found by clicking on their name.
Rodrigo Alonso
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: honorary fees for conferences and participation in advisory boards from: Tecnofarma; Saval; Novo Nordisk; Abbott/Recalcine; Boehringer-Ingelheim.
Dirk Blom
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Lecture fees / advisory board membership with Amryt; PTC; Amgen; Sanofi; AstraZeneca; MSD.
Pablo Corral
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Amgen; Sanofi; PTC; Novartis; AstraZeneca.
Ada Cuevas
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Speaker and Advisory board for: Abbott; Tecnofarma; SAVAL; Merck; TEVA; Novo Nordisk.
Samuel S. Gidding
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Esperion, consultant.
Robert Hegele
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: consulting fees from Acasti; Aegerion; Akcea/Ionis; Amgen; Arrowhead; HLS Therapeutics; Novartis; Pfizer; Regeneron; Sanofi.
Maria Cristina Izar
declares receiving honoraria for lectures, consulting fees, or investigator-initiated studies from the following companies and institutions: Amgen; Amryt Pharma; AstraZeneca; Sanofi-Aventis; EMS; Eurofarma; Novartis; Libbs; Abbott; Aché; Novo Nordisk; Servier; PTC.
Roopa Mehta
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: honoraria for giving presentations, and participating in advisory boards: Novo Nordisk; Boehringer Ingelheim; Amgen; AstraZeneca; Eli Lilly; Silanes; Sanofi.
Renan Montenegro, Jr.
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: PTC Therapeutics; Amryt; Novo Nordisk; AstraZeneca; Jansen; Takeda; Brace Pharma; Hypera Mantecorp; Abbott; Sanofi.
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: As speaker: Amgen; Novo Nordisk; PTC Therapeutics. As member of advisory boards: PTH Therapeutics.
Viviane Rocha Giraldez
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: honoraria related to lectures and consulting from: Abbott; Amgen; AstraZeneca; BIOLAB; Libbs; Novartis; Novo Nordisk.
Raul D. Santos
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector concerning consulting, speaker and or research activities from: Abbott; Aché; Amryt; AstraZeneca; Amgen; EMS; Esperion; GETZ Pharma; Kowa; Libbs; Merck; MSD; Novo Nordisk; Pfizer; PTC Therapeutics; Roche; Sanofi.
Paola Varleta
declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector: Speaker: Boehringer Ingelheim, Astra Zeneca, MSD, Novo nordisk, Bayer, Axon Pharma, Tecnofarma. Clinical Trials: Heritage (Novartis) /Horizon (Novartis) /Victotria Prevent (Novartis). Meeting Invitation: AHA 2018, Chicago Astra Zeneca / European Heart Congress, Paris 2019, Boehringer Ingelheim. Advisory Board: Axon Pharma, Novo Nordisk, Boehringer Ingelheim.
IAS planners and reviewers disclosed no financial relationship.
The IAS is very grateful to Amryt Pharma and PTC Therapeutics
for their support of this educational activity.
